(MDMA)‐Induced Toxicity by the Serotonin 2A Receptior Partial Agoni

Total Page:16

File Type:pdf, Size:1020Kb

(MDMA)‐Induced Toxicity by the Serotonin 2A Receptior Partial Agoni 84 NEUROSCIENCE RESEARCH COMMUNICATIONS, VOL. 35, NO. 2 model to date may be that of Sprague and Nichols [ 11, although it does not offer a complete accounting of the cascade of events that lead to MDMA-induced neurotoxicity. The most essential question in this field of research may be the role of the serotonin (5HT) 2A/2Creceptors, and whether activity at these receptors leads to increased or decreased release of dopamine in target structures. MDMA is a popular drug of abuse that is most commonly associated with “rave” parties [2], and recent articles have reported the mixing of d-lysergic acid diethylamide (LSD) with MDMA to increase the hallucinogenic and euphoric properties of the drug (“candy flipping” [3,4]). There has been much research exploring the neurotoxic effects following doses of MDMA in a multitude of species, and these data suggest that MDMA causes increased release of 5-HT, which in turn tonically increases dopamine release [5]. It has also been shown that 5-HT agonists such as I-(2,5-dimethoxy-4-iodophenyl)- aminopropane (DOI), melatonin, and 5-hydroxytriptamine increase this release following MDMA resulting in an increase in neurotoxicity [6]. There is disagreement as to whether 5-HT release is antagonistic [7], or agonistic [8,5] to dopamine release in brain. If 5-HT stimulates dopamine release then a partial 5-HT agonist such as LSD when given in combination with MDMA, may increase MDMA-induced neurotoxicity, and if not true then LSD may in fact provide protection. The final question is whether or not the effects of 5-HT on dopamine release are mediated primarily by the ~-HT~A and/or 5-HT2c receptors. A recent theory of MDMA-induced neurotoxicity is that abnormally high levels of dopamine are present following doses of MDMA, which is taken up via the 5-HTT and is responsible for the toxicity [9, lo]. In fact, dopamine itself has been shown to be taken up via 5-HTT and to be toxic to 5-HT terminals [ 11,12,13], and others have shown that 5-HT reuptake inhibitors (SSRIs) will block the degeneration of these terminals [5]. There have been numerous studies examining both physiological and behavioral effects in rats and humans [ 14,15,16] that suggest that the hippocampus is particularly vulnerable to MDMA-induced neurotoxicity. Therefore, we chose this structure as the focus of our immunohistological examination. The compound LSD has been characterized for many years as to its actions on 5-HT receptors, and there is a high correlation between the affinity for the ~-HT~A receptor subtype and its hallucinogenic qualities [ 171. In drug discrimination studies it has been shown that LSD transferred to drugs that were agonists at 5-HT 2~ but not 2~ receptor subtypes [ 181. Although there is evidence that suggests that LSD has actions on dopamine and other neurotransmitters in the brain, the majority of NEUROSCIENCE RESEARCH COMMUNICATIONS, VOL. 35, NO. 2 85 evidence points to LSD as being a rather powerful and selective 5-HT partial agonist, primarily at the 5- HT~A receptor site. MATERIALS AND METHODS Adult Sprague-Dawley rats bred at UCLA that weighed between 200-250 grams, were individually housed, and maintained on a reverse 12 hour light cycle at 54% humidity, and had food and water available ad-libitum throughout. Care was taken to ensure that the ambient temperature never deviated from 20°C. Animals were treated in accordance with the UCLA Animal Research Committee guidelines. Rats were administered the drugs for 4 days, were allowed to recover for 3 days, and then were perfused with 4% paraformaldehyde (for immunohistochemistry only) and sacrificed. Rats were assigned to treatment groups that received drug twice daily via subcutaneous (s.c.) injections. The treatment groups received: saline, MDMA, LSD, MDL 11,939, MDMA + LSD, and MDMA + MDL 11,939. Doses were chosen in order to provide consistency with current literature and were: MDMA; 20mg/kg/day, LSD; 25, 50, and lOOpg/kg/day, and MDL 11,939; 2.5, 5, and 7.5mglkglday. For each treatment group 6 animals were used with 4 being used for IHC and 2 for Northern blotting. Dl-3,4-methylenedioxymethamphetamine (MDMA) and d-lysergic acid diethylamide (LSD)(supplied by The National Institute of Drug Abuse) were dissolved in 0.9% saline, and animals received approximately 0.25mls per injection. The compound a-Phenyl- 1-(2-phenylethyl)-4- piperidinemethanol (MDL 11,939; supplied by Aventis Pharmaceuticals) was dissolved with 1M HCl, then 0.9% saline. The control group received 0.9% saline vehicle twice daily. The damage to pre- synaptic 5-HT terminals was assessed with antibodies that label proteins that comprise the serotonin transporter (5-HTT). The mRNA signal for serotonin transporters was quantified using cDNA probes in a Northern blotting technique. Brains used for immunohistochemistry were submerged in 4% paraformaldehyde at 4°C for 24 hours then in a 20% sucrose solution for 24 hours at 4’C before being embedded in mounting medium. Sections through the hippocampus were cut on a cryostat at 2Opm and thaw mounted onto Superfrost slides, and stored at -70°C until utilized. Slides were warmed to 20°C for 30 min. and the tissue was circled with a PAP pen, quenched with 3% Hz02 x 10 min. washed with buffer (50mM TBS) 3x5 min., treated with 3% normal serum for 1 hour, and then primary antibody over night (5-HTT; ST (C-20): ~~-1458; supplied by Santa Cruz Biotechnology Inc.). Slides were then washed in buffer 3x5 min. and treated with secondary antibody for 1 hour (ABC Vectastain Elite Kit purchased from Vector Labs). Slides were then washed in buffer and incubated in ABC substrate solution for 30 min. Slides were then washed in buffer and developed in 1XDAB for 5 min, washed in DDH20 and then buffer, dehydrated in successive EtOH baths for 2 min. each, cleared in xylene x3, and then coverglass was applied using Permount. The 5-HTT antibody that was supplied had never before been used for an immunohistochemical experiment so we first performed fixation and titration analyses to assess the proper fixative and dilution for this antibody (4% PFA; and 1: 100, respectively). Images of tissue sections were taken with a SPOT camera linked to a Zeiss microscope and a computer using Photoshop software. The region of the hippocampus was traced at the interaural level of -6.20mm, using the atlas of Paxinos and Watson [ 191, and optical densitometry measurements were taken using the NIH Image (Scion) p ro gram. Significant differences were calculated using the all pairwise multiple comparison 86 NEUROSCIENCE RESEARCH COMMUNICATIONS, VOL. 35, NO. 2 procedures using Student Newman Keuls method, and for differences from control, Dunnet’s method. Brains (without the olfactory bulbs and cerebellum) were isolated from control and treated rats, then homogenized in 4M guanidium isothiocyanate solution using an ultraturax (polytron) at 28K rpm. Total RNA was extracted as previously described [20]. RNA concentrations were estimated by spectrophotometry (Beckman DU 640B) and 60 pg of each sample were transferred into eppendorf tubes prior to evaporation under vaccum (speedvac). Pellets were reconstituted in 30 ~1 of 1X BOH- DNB loading buffer containing p-mercaptoethanol. Heat-denaturated RNA samples were loaded into a 0.8 % agarose / 2% formaldehyde gel. Migration was conducted at 4’C using 80V for 2.5 hrs. Gels were photographed using a digital gel documentation system (Lighthouse Research Speedlight) then transferred overnight onto nylon membranes (Turboblotter, Schliecher & Schull). Blots were rinsed, baked, and UV-crosslinked prior to hybridization. Membranes were first prehybridized for 2 hrs, and then hybridized with 400,000 cpm/~l [32P]-random labeled probe (Invitrogen) for 16 hrs in UltrahybTM hybridization solution (Ambion) at 44OC. Hybridizations were performed sequentially (SHTT and cyclophillin, respectively). For 5-HTT, a 1040bp selective cDNA probe encoding for the 5HTT transcript was excised using Xho-1 restriction enzyme from Bluescript SK- plasmid (generously supplied by Dr. Randy Blakely at Vanderbilt University).The rat cyclophillin 650bp probe was PCR- generated and inserted in TOPO-PCR4 vector prior to amplification in TOP10 cells (Invitrogen). Probe was prepared by excision using EcoRl restriction enzyme. Nature of the insert was confirmed by sequencing. Membranes were washed twice in 2X SSC, 0.1% SDS solution at 44OC for 5 min., and then washed twice in 0.1X SSC, 0.1% SDS for 15 min. at 44OC. After a 3 day-exposure, signals were detected by a Phosphorimager (Molecular Dynamics Inc.) and analyzed using ImageQuant software. In order to combine the data obtained from the blots the values were expressed as percent of control, so that measures were normalized against the cyclophillin signal in each group. Statistical analysis was accomplished using Sigma Stat (Jandel Scientific), and graphs were generated using Graph Pad (Prism) software. RESULTS It was hypothesized that the MDMA-treated animals would show 5-HT terminal loss, and that the MDMA + LSD group would show more damage to the brain than those given MDMA alone. We also expected that the blocking action of the 5-HT 2~2~ receptor antagonist MDL 11,939 would decrease the toxicity seen in the MDMA + MDL 11,939 group in comparison to the MDMA-alone treated group. The damage to the brain was defined as the loss of 5-HT terminals, primarily in the hippocampus, as toxic effects in this structure are among the most consistent findings among researchers [ 14,151. It is evident from the results that LSD had a synergistic effect when given in conj unction with MDMA. The immunohistochemical staining shows a dramatic decrease in 5-HTTs in the hippocampus (Fig.
Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • AGENDA Friday, September 9, 2016 7:00 A.M
    Needham Board of Health AGENDA Friday, September 9, 2016 7:00 a.m. – 9:00 a.m. Charles River Room – Public Services Administration Building 500 Dedham Avenue, Needham MA 02492 • 7:00 to 7:05 - Welcome & Review of Minutes (July 29 & August 29) • 7:05 to 7:30 - Director and Staff Reports (July & August) • 7:30 to 7:45 - Discussion about Proposed Plastic Bag Ban Christopher Thomas, Needham Resident • 7:45 to 7:50 - Off-Street Drainage Bond Discussion & Vote • 7:50 to 8:00 - Update on Wingate Pool Variance Application * * * * * * * * * * * * * Board of Health Public Hearing • 8:00 to 8:40 - Hearing for Proposed New or Amended BOH Regulations o Body Art o Synthetic Marijuana o Drug Paraphernalia • 8:40 to 8:50 - Board Discussion of Policy Positions • Other Items (Healthy Aging, Water Quality) • Next Meeting Scheduled for Friday October 14, 2016 • Adjournment (Please note that all times are approximate) 1471 Highland Avenue, Needham, MA 02492 781-455-7500 ext 511 (tel); 781-455-0892 (fax) E-mail: [email protected] Web: www.needhamma.gov/health NEEDHAM BOARD OF HEALTH July 29, 2016 MEETING MINUTES PRESENT: Edward V. Cosgrove, PhD, Chair, Jane Fogg, Vice-Chair, M.D., and Stephen Epstein, M.D STAFF: Timothy McDonald, Director, Donna Carmichael, Catherine Delano, Maryanne Dinell, Tara Gurge GUEST: Kevin Mulkern, Aquaknot Pools, Inc., Keith Mulkern, Aquaknot Pools, Inc., David Friedman, Wingate, Paul Humphreys, Michael Tomasello, Callahan, Inc. CONVENE: 7:00 a.m. – Public Services Administration Building (PSAB), 500 Dedham Avenue, Needham MA 02492 DISCUSSION: Call To Order – 7:06 a.m. – Dr. Cosgrove, Chairman APPROVE MINUTES: Upon motion duly made and seconded, the minutes of the BOH meeting of June 17, 2016 were approved as submitted.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • STORY COUNTY BOARD of HEALTH TENTATIVE AGENDA TUESDAY, April 6, 2021 2:00 PM
    STORY COUNTY BOARD OF HEALTH TENTATIVE AGENDA TUESDAY, April 6, 2021 2:00 PM Originating via Zoom from - Story County Administration (900 6th Street)– Nevada, Iowa SPECIAL NOTE TO THE PUBLIC: Due to recommendations to social distance in order to help slow the spread of the COVID-19 virus, the capacity of our meeting room is significantly limited. Therefore public access to the meeting will be provided via Zoom. Members of the public can participate by using the information located at the bottom of this agenda. 1. CALL TO ORDER 2. APPROVAL OF AGENDA 3. APPROVAL OF MINUTES Documents: 020221.PDF 031121.PDF 4. CONSENT AGENDA All items listed under the consent agenda will be enacted by one motion. There will be no separate discussion of these items unless a request is made prior to the time the Board votes on the motion. 5. PUBLIC FORUM This is the time for members of the public to offer comments concerning matters not scheduled to be heard before the Board of Health. 6. ADDITIONAL ITEMS 6.I. Recognition Of Cathy Bazylinski For Her 16 Years Of Service 6.II. Discussion And Consideration Of Recruitment Process For Environmental Health Director - Alissa Wignall Documents: DIRECTOR OF ENVIRONMENTAL HEALTH VACANCY.PDF ENVIRONMENTAL HEALTH DIRECTOR JOB DESCRIPTION.PDF 6.III. COVID-19 Update On Current Cases And Vaccine Distribution - Les White Documents: PUBLIC HEALTH UPDATE.PDF 6.IV. Discussion Of Face Covering Regulation - Importance Of Wearing A Face Covering And Criteria For Recommending Removal Of Regulation 6.V. Arsenic In Private Water Wells - Cathy Bazylinski Documents: ARSENIC FACT SHEET.PDF 6.VI.
    [Show full text]
  • Eu Early Warning System Situation Report
    EU EARLY WARNING SYSTEM SITUATION REPORT Situation report 1 — June 2020 SITREP ID: EU-EWS-SITREP-2020-0001 Issued by: EMCDDA Date issued: 16/06/2020 Transmitted by: Action on New Drugs Sector, EMCDDA Recipients: Early Warning System Network Contents 1. Purpose 2 2. General update of the NPS situation 2 3. Operational matters 7 4. Subject focus: Potential impact of the COVID-19 pandemic on the drug markets and risks to people who use drugs 8 5. Update from the national early-warning systems 11 6. Publications and resources of interest 11 7. New psychoactive substances notified in 2020 — provisional list, 1 January–16 June 2020 13 8. References 15 EU-EWS-SITREP-2020-0001 1 of 16 1. Purpose The purpose of this situation report is to: provide a summary of recent information reported to the EU Early Warning System, including formal notifications and other important signals; highlight important operational issues; and, provide other resources identified by the EMCDDA. This report may contain information that might be under verification. The information and resources in this report are intended to strengthen situational awareness within the Network, as well as to help the Network to prepare for, respond to, and recover from public health and social threats caused by new psychoactive substances (NPS) and other substances of interest. A specific focus of this report is to: • highlight recent resources that examine the potential impact of the COVID-19 pandemic on the drug markets and risks to people who use drugs; and, • request that the Network expedite reporting of any event, especially those related to the pandemic, that you consider may have a potential high impact on public health.
    [Show full text]
  • AGENDA Friday, June 17, 2016 7:00 A.M
    Needham Board of Health AGENDA Friday, June 17, 2016 7:00 a.m. – 8:45 a.m. Charles River Room – Public Services Administration Building 500 Dedham Avenue, Needham MA 02492 • 7:00 to 7:05 - Welcome & Review of Minutes • 7:05 to 7:30 - Director and Staff Reports • 7:30 to 8:15 - Continued Discussion of Proposed New or Amended BOH Regulations o Body Art o Synthetic Marijuana o Drug Paraphernalia • 8:15 to 8:45 - Board Discussion of Policy Positions • Other Items • Next Meeting Scheduled for Friday July 29, 2016 • Adjournment (Please note that all times are approximate) 1471 Highland Avenue, Needham, MA 02492 781-455-7500 ext 511 (tel); 781-455-0892 (fax) E-mail: [email protected] Web: www.needhamma.gov/health NEEDHAM BOARD OF HEALTH May 13, 2016 MEETING MINUTES PRESENT: Edward V. Cosgrove, PhD, Chair, Stephen Epstein, M.D., Vice-Chair, and Jane Fogg, M.D. STAFF: Timothy McDonald, Director, Catherine Delano, Maryanne Dinell, Tara Gurge, Alison Paquette GUEST: Christopher Coleman, Assistant Town Manager, Charles Poljoniz, 7-11, Ghassan Mohammed, 7- 11, Chestnut Street, Needham, MA, Karen Simao, Attorney for 7-11, Laura Miller, 7-11 CONVENE: 7:00 a.m. – Public Services Administration Building (PSAB), 500 Dedham Avenue, Needham MA 02492 DISCUSSION: Call To Order – 7:02 a.m. – Dr. Cosgrove Approve Minutes: Upon motion duly made and seconded, the minutes of the BOH meeting of April 1, 2016 were approved as submitted. The motion carried. The vote was unanimous. Director’s Report – Timothy McDonald Mr. McDonald welcomed Catherine Delano. Ms. Delano was offered and has accepted the position of Senior Substance Use Prevention Program Coordinator.
    [Show full text]
  • Toronto Overdose Action Plan: Status Report 2020
    HL17.2 REPORT FOR ACTION Toronto Overdose Action Plan: Status Report 2020 Date: May 29, 2020 To: Board of Health From: Medical Officer of Health Wards: All SUMMARY The ongoing opioid poisoning crisis in Toronto and across Canada has intensified and been further compounded by the COVID-19 global pandemic. These dual public health crises are having significant impacts on people who use drugs in our community as well as their families, friends and loved ones. Services that people rely on, many of them lifesaving, have closed or significantly reduced their service hours and/or capacity. During the first four months of 2020, paramedics responded to 1,307 suspected opioid overdose calls, including 71 calls involving deaths. In April 2020, paramedics responded to the highest number of suspected opioid overdose deaths (25) since September 2017. This staff report highlights actions taken to implement the Toronto Overdose Action Plan since the last status report in June 2019 and includes issues related to the COVID-19 pandemic. The report also recommends additional urgent actions that are needed to address the opioid poisoning crisis, especially in the context of the pandemic and the increasingly toxic unregulated drug supply. The need for a fundamental change toward a public health approach remains critical to improving the health outcomes of people who use drugs. Toronto Public Health remains committed to working with our community and institutional partners to improve our collective overdose prevention and response efforts, and to improving the health and well-being of people who use drugs, which is even more of an imperative during this time of dual public health crises.
    [Show full text]
  • Forensic Chemistry of Substance Misuse a Guide to Drug Control
    Forensic Chemistry of Substance Misuse A Guide to Drug Control Forensic Chemistry of Substance Misuse A Guide to Drug Control L. A. King ISBN: 978-0-85404-178-7 A catalogue record for this book is available from the British Library r L. A. King 2009 All rights reserved Apart from fair dealing for the purposes of research for non-commercial purposes or for private study, criticism or review, as permitted under the Copyright, Designs and Patents Act 1988 and the Copyright and Related Rights Regulations 2003, this publication may not be reproduced, stored or transmitted, in any form or by any means, without the prior permission in writing of The Royal Society of Chemistry or the copyright owner, or in the case of reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK, or in accordance with the terms of the licences issued by the appropriate Reproduction Rights Organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to The Royal Society of Chemistry at the address printed on this page. Published by The Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge CB4 0WF, UK Registered Charity Number 207890 For further information see our web site at www.rsc.org Preface ‘‘Gold is worse poison to a man’s soul, doing more murders in this loathsome world, than any mortal drug’’ William Shakespeare (Romeo and Juliet) An earlier publication1 described the UK drugs legislation from the viewpoint of a forensic scientist. In the current book, an opportunity has been taken to rearrange and expand the material and improve clarity, to include the changes that have occurred in the past six years, and, more importantly, to widen the scope and the intended audience.
    [Show full text]
  • BOH Agenda Packet May 13, 2016
    Needham Board of Health AGENDA Friday, May 13, 2016 7:00 a.m. – 8:30 a.m. Charles River Room – Public Services Administration Building 500 Dedham Avenue, Needham MA 02492 7:00 to 7:05 - Welcome & Review of Minutes 7:05 to 7:30 - Director and Staff Reports * * * * * * * * * * * * * Board of Health Public Hearing 7:30 to 8:00 - Administrative Hearing about Tobacco Regulation (Article #1) Violations—Sale to Underage Persons * * * * * * * * * * * * * 8:00 to 8:20 - Discussion of Proposed New or Amended BOH Regulations o Body Art o Synthetic Marijuana o Drug Paraphernalia 8:20 to 8:30 - Board Discussion of Policy Positions Other Items Next Meeting Scheduled for Friday June 10, 2016 Adjournment (Please note that all times are approximate) 1471 Highland Avenue, Needham, MA 02492 781-455-7500 ext 511 (tel); 781-455-0892 (fax) E-mail: [email protected] Web: www.needhamma.gov/health NEEDHAM BOARD OF HEALTH April 1, 2016 MEETING MINUTES PRESENT: Stephen Epstein, M.D., Chair, Edward V. Cosgrove, Ph.D. Vice-Chair, and Jane Fogg, M.D. STAFF: Timothy McDonald, Director, Maryanne Dinell, Tara Gurge, Carol Read GUEST: David A. Lawson, Director, Norfolk County Mosquito Control District, Patty Carey, Director of Parks & Recreation, Christopher Coleman, Assistant Town Manager/Director of Operations CONVENE: 7:00 a.m. – Public Services Administration Building (PSAB), 500 Dedham Avenue, Needham MA 02492 DISCUSSION: Call To Order – 7:03 am – Dr. Epstein Approve Minutes: Upon motion duly made and seconded, the minutes of the BOH meeting of February 12, 2016 were approved as submitted. The motion carried. The vote was unanimous.
    [Show full text]
  • New Psychoactive Substances: Global Markets, Glocal Threats and the COVID-19 Pandemic
    New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic An update from the EU Early Warning System December 2020 Front cover photos 1. ‘Ching’ typically sold as a ‘legal’ replacement to cocaine. In this case the product contained methoxyacetylfentanyl. Credit: Slovenian National Forensic Laboratory (Police). 2. Plant material from a ‘Spice’ product that contained CP-47,497 C8 homolog. Credit: Slovenian National Forensic Laboratory (Police). 3. Package containing CUMYL-4CN-BINACA powder that shipped from China. Credit: Slovenian National Forensic Laboratory (Police). 4. Fake Xanax tablets that contained cyclopropylfentanyl. Credit: WR Brede, H-M Krabseth and co-workers, St. Olav University Hospital, Trondheim, Norway. New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic An update from the EU Early Warning System December 2020 I Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained in this document. The contents of this publication do not necessarily reflect the official opinions of the EMCDDA’s partners, any EU Member State or any agency or institution of the European Union. Luxembourg: Publications Office of the European Union, 2020 © European Monitoring Centre for Drugs and Drug Addiction, 2020 Reproduction is authorised provided the source is acknowledged. For any use or reproduction of photos that are not under EMCDDA copyright, permission must be sought directly from the copyright holders. Photo credits for the front cover images: Laboratorio de Drogas (Servicio de Química), Instuto Nacional de Toxicología y Ciencias Forenses (INTyCF) Barcelona (1, 2), Hungarian Institute for Forensic Sciences (3), P.
    [Show full text]
  • Development of Methods for the Detection of Novel Psychoactive Substances in Oral Fluid
    Development of methods for the detection of Novel Psychoactive Substances in Oral Fluid Michelle Williams BSc (Physiology); MBD/MDR (Townsville) M Clin Tox (Florida) A Thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy in Medicine August 2018 This research was supported by an Australian Government Research Training Program (RTP) Scholarship i Declarations STATEMENT OF ORIGINALITY I hereby certify that the work embodied in the Thesis is my own work, conducted under normal supervision. The Thesis contains no material which has been accepted, or is being examined, for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made. I give consent to the final version of my Thesis being made available worldwide when deposited in the University’s Digital Repository, subject to the provisions of the Copyright Act 1968 and any approved embargo. Michelle Williams 09/08/18 ii Statement of Authorship I hereby certify that the work embodied in this Thesis contains published paper/s/scholarly work of which I am a joint author. I have included as part of the thesis a written declaration endorsed in writing by my supervisor, attesting to my contribution to the joint publication/s/scholarly work. Thesis by publication I hereby certify that this Thesis is in the form of a series of papers. I have included as part of the Thesis a written declaration from each co-author, endorsed in writing by the Faculty Assistant Dean (Research Training), attesting to my contribution to any jointly authored papers.
    [Show full text]
  • A Magyarországon Megjelent, a Kábítószer És Kábítószer-Függőség
    A Magyarországon megjelent, a Kábítószer és Kábítószer-függőség Európai Megfigyelő Központjának Korai Jelzőrendszerébe (EMCDDA EWS) 2005 óta bejelentett ellenőrzött anyagok büntetőjogi vonatkozású besorolása Név Egyéb nevek* Jogi státusz (2021. június 11-i állapot szerint) Megjegyzések** 1-nafiron nafiron 2012. április 3-tól új pszichoaktív anyag, UP jegyzék 5. felsorolásában szereplő anyag 2015. január 1-től büntetőjogilag kábítószernek minősül 2005. évi XCV. törvény 2. mellékletének "A" jegyzéke 1P-LSD 2016. július 11-től új pszichoaktív anyag UP jegyzék 5. felsorolásában szereplő anyag 2,3-MDPV 2,3-Methylenedioxy- 2012. április 3-tól új pszichoaktív anyagnak minősül. UP jegyzék 2. szerkezeti leírásának megfelelő anyag pyrovalerone 25B-N(BOMe)2 2012. április 3-tól új pszichoaktív anyag UP jegyzék 4. szerkezeti leírásának megfelelő anyag 25B-NBOMe 2012. április 3-tól új pszichoaktív anyag UP jegyzék 4. szerkezeti leírásának megfelelő anyag 25C-NBOMe 2012. április 3-tól új pszichoaktív anyag UP jegyzék 4. szerkezeti leírásának megfelelő anyag 25I-NBF 2015. július 11-től új pszichoaktív anyag UP jegyzék 5. felsorolásában szereplő anyag 25I-NBOMe 2012. április 3-tól új pszichoaktív anyag, UP jegyzék 4. szerkezeti leírásának megfelelő anyag 2015. január 1-től büntetőjogilag kábítószernek minősül 2005. évi XCV. törvény 2. mellékletének "A" jegyzéke 2C-B-FLY 2012. április 3-tól új pszichoaktív anyag UP jegyzék 4. szerkezeti leírásának megfelelő anyag 2C-C 2012. április 3-tól új pszichoaktív anyag UP jegyzék 4. szerkezeti leírásának megfelelő anyag 2C-D 2012. április 3-tól új pszichoaktív anyag UP jegyzék 4. szerkezeti leírásának megfelelő anyag 2C-E 2012. április 3-tól új pszichoaktív anyag UP jegyzék 4.
    [Show full text]